Expand all sections

Dupilumab

Dupixent

Extended indication Dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (PN) who
Therapeutic value Possible added value
Total cost 3,000,000.00
Registration phase Registered and reimbursed

Product

Registration

Therapeutic value

Expected patient volume per year

Expected cost per patient per year

Potential total cost per year

Off label use

Indication extension

Other information